226. 間質性膀胱炎(ハンナ型) Interstitial cystitis with Hunners ulcer Clinical trials / Disease details
臨床試験数 : 143 / 薬物数 : 171 - (DrugBank : 56) / 標的遺伝子数 : 64 - 標的パスウェイ数 : 145
Showing 1 to 10 of 143 diseases
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT05062902 (ClinicalTrials.gov) | January 1, 2023 | 16/9/2021 | A Novel Medical System for Quantitative Diagnosis and Personalized Precision Botulinum Neurotoxin Injection in Chronic Pelvic Pain Management A Novel Medical System for Quantitative Diagnosis and Personalized Precision Botulinum Neurotoxin In ... | An Novel Medical System for Quantitative Diagnosis and Personalized Precision Botulinum Neurotoxin Injection in Chronic Pelvic Pain Management An Novel Medical System for Quantitative Diagnosis and Personalized Precision Botulinum Neurotoxin I ... | Interstitial Cystitis;Chronic Pain;Pelvic Floor; Relaxation;Pelvic Floor Disorders | Device: High Density Surface Electromyographic, precision botulinum neurotoxin injection guidance medical device;Drug: Botulinum Neurotoxin Device: High Density Surface Electromyographic, precision botulinum neurotoxin injection guidance me ... | HillMed Inc. | Baylor College of Medicine;University of Houston | Not yet recruiting | 18 Years | 60 Years | Female | 46 | Early Phase 1 | United States |
2 | NCT04734106 (ClinicalTrials.gov) | May 2022 | 27/1/2021 | Safety and Efficacy of Aloe Vera in the Management of the Symptoms of Interstitial Cystitis | A Double-Blind, Placebo-Controlled Study to Establish the Safety and Efficacy of Super-Concentrated, Freeze-Dried Aloe Vera in the Management of the Symptoms of Interstitial Cystitis A Double-Blind, Placebo-Controlled Study to Establish the Safety and Efficacy of Super-Concentrated, ... | Interstitial Cystitis;Chronic Interstitial Cystitis;Bladder Pain Syndrome | Drug: Desert Harvest Aloe Vera Capsules;Other: Placebo Capsules | Wake Forest University Health Sciences | Desert Harvest | Not yet recruiting | 18 Years | N/A | All | 100 | Early Phase 1 | United States |
3 | NCT05147779 (ClinicalTrials.gov) | December 2021 | 29/11/2021 | Safety of Cultured Allogeneic Adult Umbilical Cord Stem Cells for Peyronie's Disease, ED, and Interstitial Cystitis Safety of Cultured Allogeneic Adult Umbilical Cord Stem Cells for Peyronie's Disease, ED, and Inters ... | Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for the Treatment of Peyronie's Disease, Erectile Dysfunction, and Interstitial Cystitis Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for the Treatment ... | Erectile Dysfunction;Peyronie's Disease;Interstitial Cystitis | Biological: AlloRx | The Foundation for Orthopaedics and Regenerative Medicine | NULL | Recruiting | N/A | N/A | All | 20 | Phase 1 | Antigua and Barbuda |
4 | JPRN-jRCTs051210106 | 13/10/2021 | 13/10/2021 | ESTOC study | The Effect of Suplatast Tosilate for interstitial Cystitis: A randomized controlled open-label trial - ESTOC study The Effect of Suplatast Tosilate for interstitial Cystitis: A randomized controlled open-label trial ... | Interstitial cystitis bladder, inflammation, pain;D018856 | Participants will be randomly assigned to splatast group or control group. In splatast group, splatast tosilate capsule 100 mg (1 capsule at a time) will be orally administered 3 times a day between meals for 3 months. In control group, flavoxate hydrochloride tablets 200 mg (1 tablet at a time) will be orally administered 3 times a day between meals for 3 months. Participants will be randomly assigned to splatast group or control group. In splatast group, splatas ... | Torimoto Kazumasa | Fujimoto Kiyohide | Recruiting | >= 20age old | Not applicable | Both | 100 | Phase 2 | Japan |
5 | NCT04845217 (ClinicalTrials.gov) | September 15, 2021 | 29/3/2021 | Peppermint Oil for the Treatment of Interstitial Cystitis / Bladder Pain Syndrome | Efficacy of Peppermint Oil in a Randomized, Single-Blind, Placebo Controlled Trial in Women With Interstitial Cystitis/Bladder Pain Syndrome Efficacy of Peppermint Oil in a Randomized, Single-Blind, Placebo Controlled Trial in Women With Int ... | Interstitial Cystitis | Drug: Peppermint oil;Drug: Coconut Oil | University of Louisville | Integrative Therapeutics, Inc. | Recruiting | 18 Years | 65 Years | Female | 100 | Phase 1/Phase 2 | United States |
6 | NCT04313972 (ClinicalTrials.gov) | September 7, 2021 | 16/3/2020 | IC PaIN Trial: Interstitial Cystitis Pain Improvement With Naltrexone | IC PaIN Trial: Interstitial Cystitis Pain Improvement With Naltrexone, the Effect of Low Dose Naltrexone on Symptoms and Pain of Patients With Interstitial Cystitis/Painful Bladder Syndrome a Randomized Placebo-controlled Prospective Trial IC PaIN Trial: Interstitial CystitisPain Improvement With Naltrexone, the Effect of Low Dose Naltrex ... | Interstitial Cystitis;Painful Bladder Syndrome;Bladder Pain Syndrome;Low Dose Naltrexone;Low-dose Naltrexone;Naltrexone Interstitial Cystitis;Painful Bladder Syndrome;Bladder Pain Syndrome;Low Dose Naltrexone;Low-dose Na ... | Drug: low-dose naltrexone;Drug: Placebo oral tablet | NorthShore University HealthSystem | NULL | Recruiting | 18 Years | 110 Years | Female | 44 | Phase 4 | United States |
7 | NCT05275647 (ClinicalTrials.gov) | May 18, 2021 | 13/1/2022 | Efficacy and Safety of Low Energy Shock Wave Plus BotulinumToxin A in Treating Patients With Interstitial Cystitis Efficacy and Safety of Low Energy Shock Wave Plus BotulinumToxin A in Treating Patients With Interst ... | Therapeutic Efficacy and Safety of Low Energy Shock Wave (LESW) Plus Botulinum Toxin A Instillation in Treatment of Patients With Interstitial Cystitis Refractory to Conventional Therapy - A Clinical and Immunohistochemistry Study Therapeutic Efficacy and Safety of Low Energy Shock Wave (LESW) Plus Botulinum Toxin A Instillation ... | Interstitial Cystitis | Drug: BOTOX 100U in normal saline;Drug: Normal saline | Buddhist Tzu Chi General Hospital | Ministry of Science and Technology, Taiwan;Hualien Tzu Chi General Hospital | Recruiting | 20 Years | N/A | All | 75 | Phase 2 | Taiwan |
8 | NCT04349930 (ClinicalTrials.gov) | January 2021 | 13/4/2020 | The CBD-IC Randomized Controlled Trial: Evaluation of Hemp Cannabidiol SuppositoRies for Pain and Urinary SymptOms in INterstitial Cystitis (CHRONIC) The CBD-IC Randomized Controlled Trial: Evaluation of Hemp Cannabidiol SuppositoRies for Pain and Ur ... | The CBD-IC Randomized Controlled Trial: Evaluation of Hemp Cannabidiol SuppositoRies for Pain and Urinary SymptOms in INterstitial Cystitis (CHRONIC) The CBD-IC Randomized Controlled Trial: Evaluation of Hemp Cannabidiol SuppositoRies for Pain and Ur ... | Interstitial Cystitis;Bladder Pain Syndrome | Drug: Cannabidiol vaginal suppository;Drug: Placebo vaginal suppository | University of New Mexico | NULL | Withdrawn | 18 Years | N/A | Female | 0 | Phase 1 | United States |
9 | NCT04610359 (ClinicalTrials.gov) | October 20, 2020 | 19/10/2020 | Safety of Human Embryonic Stem Cell (hESC)-Derived Mesenchymal Stem Cells in Interstitial Cystitis | Safety of Human Embryonic Stem Cell (hESC)-Derived Mesenchymal Stem Cells in Interstitial Cystitis; Open-labelled, Single Center, Phase 1 Study Safety of Human Embryonic Stem Cell (hESC)-Derived Mesenchymal Stem Cells in Interstitial Cystitis; ... | Interstitial Cystitis;Stem Cell Transplant;Mesenchymal Stem Cell | Drug: MR-MC-01 | Asan Medical Center | MIRAE CELL BIO | Recruiting | 20 Years | N/A | Female | 3 | Phase 1 | Korea, Republic of |
10 | NCT04447729 (ClinicalTrials.gov) | October 15, 2020 | 10/6/2020 | A Study to Test if Fremanezumab Reduces Pain in Patients With Interstitial Cystitis-Bladder Pain Syndrome A Study to Test if Fremanezumab Reduces Pain in Patients With Interstitial Cystitis-Bladder Pain Syn ... | A Multicenter, Open-label Pilot Study of the Efficacy and Safety of Fremanezumab for Treatment of Female Patients With Interstitial Cystitis-Bladder Pain Syndrome A Multicenter, Open-label Pilot Study of the Efficacy and Safety of Fremanezumab for Treatment of Fe ... | Interstitial Cystitis | Drug: fremanezumab | Teva Branded Pharmaceutical Products R&D, Inc. | NULL | Withdrawn | 18 Years | N/A | Female | 0 | Phase 2 | NULL |